Inhibiting PP2A reduces MECP2 in neuropsychiatric model

In a paper published in Science Translational Medicine, researchers showed that inhibiting protein phosphatase 2 (PP2A; PPP2CA) reduced levels of methyl CpG binding protein 2 (MECP2; RTT), suggesting that modulating PP2A could treat neuropsychiatric conditions, including MECP2 duplication syndrome and Rett syndrome, a risk factor for autism.

Both syndromes are characterized by intellectual disability, autistic features and motor dysfunction. The authors said these features are a result of a two-fold increase of MECP2 in patients with MECP2 duplication syndrome, and of a decrease or loss of the protein in about 50% of cells in females with Rett syndrome...